Sun Pharmaceutical Industries, India’s largest pharmaceutical company, maintains a robust business model centered on specialty generics, branded formulations, and active pharmaceutical ingredients (APIs). With a strong global presence, particularly in the US and emerging markets like Brazil and South Africa, it derives significant revenue from its diversified portfolio, including chronic therapies and high-margin specialty drugs like Leqselvi for alopecia. Strategic acquisitions, such as Checkpoint Therapeutics and Concert Pharma, bolster its oncology and dermatology segments, while consistent R&D investment (6-8% of revenue) drives innovation in complex formulations. Despite challenges like US tariff threats and manufacturing-related recalls, Sun Pharma’s focus on specialty portfolio expansion and stable domestic growth in India positions it for resilient revenue growth, with analysts projecting steady earnings supported by new launches and a recovering US generics market.